Citius Oncology, Inc. CTOR Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s share-based payment award options outstanding - number?
- Citius Oncology, Inc. (CTOR) reported share-based payment award options outstanding - number of 18.1M in Q3 2026.
- How has Citius Oncology, Inc.'s share-based payment award options outstanding - number changed year-over-year?
- Citius Oncology, Inc.'s share-based payment award options outstanding - number decreased by 0.0% year-over-year, from 18.1M to 18.1M.
- What is the long-term trend for Citius Oncology, Inc.'s share-based payment award options outstanding - number?
- Over 3 years (2023 to 2026), Citius Oncology, Inc.'s share-based payment award options outstanding - number has grown at a 12.8% compound annual growth rate (CAGR), from 12.6M to 18.1M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.